Clinical trial
Post-marketing Observational Study of Remitoro® Intravenous Injection 300 μg - Safety of Remitoro in Patients With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
NCT05137847 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post-marketing Observational Study of Remitoro® Intravenous Injection 300 μg - Safety of Remitoro in Patients With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
- Lead sponsor
- Eisai Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 24, 2021
- Completion date
- March 17, 2023
- Enrollment
- 118 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.